Collegium Pharmaceutical, Inc (COLL) stock
COLLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 14/3048% below fair value
$25.43+0.11 (+0.43%)
Close on Nov 16, 2026Market cap $827.89MP/E 20.5Yield –
Collegium Pharmaceutical operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Collegium Pharmaceutical's operating income for the twelve months ending Jun 30, 2026 was $157.44M, up 21.3% year over year. For fiscal 2025 it was $179.64M, up 5.7% from the year before. The highest annual figure on record is $179.64M in fiscal 2025.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $179.64M | +5.7% |
| FY2024 | Dec 31, 2024 | $169.90M | +1.8% |
| FY2023 | Dec 31, 2023 | $166.96M | +401.1% |
| FY2022 | Dec 31, 2022 | $33.32M | +89.0% |
| FY2021 | Dec 31, 2021 | $17.63M | -68.7% |
| FY2020 | Dec 31, 2020 | $56.23M | – |
| FY2019 | Dec 31, 2019 | -$23.75M | – |
| FY2018 | Dec 31, 2018 | -$20.69M | – |
| FY2017 | Dec 31, 2017 | -$75.45M | – |
| FY2016 | Dec 31, 2016 | -$94.08M | – |
| FY2015 | Dec 31, 2015 | -$26.91M | – |
| FY2014 | Dec 31, 2014 | -$17.67M | – |
| FY2013 | Dec 31, 2013 | -$16.04M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $3.70M | -89.5% |
| Q1 FY2026 | Mar 31, 2026 | $30.90M | +42.5% |
| Q4 FY2025 | Dec 31, 2025 | $60.76M | +59.4% |
| Q3 FY2025 | Sep 30, 2025 | $62.09M | +78.2% |
| Q2 FY2025 | Jun 30, 2025 | $35.11M | -26.0% |
| Q1 FY2025 | Mar 31, 2025 | $21.69M | -56.2% |
| Q4 FY2024 | Dec 31, 2024 | $38.11M | -38.2% |
| Q3 FY2024 | Sep 30, 2024 | $34.84M | -22.6% |
| Q2 FY2024 | Jun 30, 2024 | $47.47M | +33.2% |
| Q1 FY2024 | Mar 31, 2024 | $49.47M | +100.9% |
| Q4 FY2023 | Dec 31, 2023 | $61.69M | +424.7% |
| Q3 FY2023 | Sep 30, 2023 | $45.01M | +119.9% |
| Q2 FY2023 | Jun 30, 2023 | $35.63M | +220.7% |
| Q1 FY2023 | Mar 31, 2023 | $24.63M | – |
| Q4 FY2022 | Dec 31, 2022 | $11.76M | – |
| Q3 FY2022 | Sep 30, 2022 | $20.47M | +44.7% |
| Q2 FY2022 | Jun 30, 2022 | $11.11M | -32.3% |
| Q1 FY2022 | Mar 31, 2022 | -$10.02M | -147.3% |
| Q4 FY2021 | Dec 31, 2021 | -$34.12M | -327.5% |
| Q3 FY2021 | Sep 30, 2021 | $14.15M | -27.9% |
| Q2 FY2021 | Jun 30, 2021 | $16.41M | -0.8% |
| Q1 FY2021 | Mar 31, 2021 | $21.19M | +318.7% |
| Q4 FY2020 | Dec 31, 2020 | $15.00M | – |
| Q3 FY2020 | Sep 30, 2020 | $19.63M | – |
| Q2 FY2020 | Jun 30, 2020 | $16.55M | – |
| Q1 FY2020 | Mar 31, 2020 | $5.06M | – |
| Q4 FY2019 | Dec 31, 2019 | -$2.37M | -121.6% |
| Q3 FY2019 | Sep 30, 2019 | -$6.38M | – |
| Q2 FY2019 | Jun 30, 2019 | -$5.01M | – |
| Q1 FY2019 | Mar 31, 2019 | -$9.99M | – |
| Q4 FY2018 | Dec 31, 2018 | $11.00M | – |
| Q3 FY2018 | Sep 30, 2018 | -$11.19M | – |
| Q2 FY2018 | Jun 30, 2018 | -$7.29M | – |
| Q1 FY2018 | Mar 31, 2018 | -$13.21M | – |
| Q4 FY2017 | Dec 31, 2017 | -$17.58M | – |
| Q3 FY2017 | Sep 30, 2017 | -$13.43M | – |
| Q2 FY2017 | Jun 30, 2017 | -$21.26M | – |
| Q1 FY2017 | Mar 31, 2017 | -$23.18M | – |
| Q4 FY2016 | Dec 31, 2016 | -$27.58M | – |
| Q3 FY2016 | Sep 30, 2016 | -$26.44M | – |
See a number that looks wrong?